BRAF and melanoma: BRAF heterogeneity has significant implications when using RAF kinase inhibitors because, in contrast to BRAFV600E melanoma cells, BRAF wild-type cells are resistant to (and may even be stimulated by) RAF kinase inhibitors (Hatzivassiliou et al, 2010; Heidorn et al, 2010).